Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym024 Monotherapy and in Combination With Sym021 in Advanced Solid Tumors
NCT04672434Phase 1Completed
- Sponsor
- Symphogen
- Start
- Nov 2020
- Primary completion
- Nov 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of sym024 in solid tumor, squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC) and 7 more (11 arms), sponsored by Symphogen. Primary endpoint: Incidence, severity and relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months. Started Nov 2020; status: completed.
02
Drugs
sym024
03
Conditions
solid tumorsquamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04672434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672434.